{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:40:02Z","timestamp":1793972402594,"version":"4.8.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010663","name":"ERC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.tips.2021.05.001","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T08:43:02Z","timestamp":1622623382000},"page":"640-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":295,"title":["Iron metabolism: pathophysiology and pharmacology"],"prefix":"10.1016","volume":"42","author":[{"given":"Karolin","family":"Roemhild","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"von Maltzahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Weiskirchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Kn\u00fcchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"von Stillfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Twan","family":"Lammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2021.05.001_bb0005","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1357-2725(01)00063-2","article-title":"Chemistry and biology of eukaryotic iron metabolism","volume":"33","author":"Aisen","year":"2001","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.tips.2021.05.001_bb0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/nrd.2016.248","article-title":"Targeting iron metabolism in drug discovery and delivery","volume":"16","author":"Crielaard","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2021.05.001_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nchembio.1416","article-title":"The role of iron and reactive oxygen species in cell death","volume":"10","author":"Dixon","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.tips.2021.05.001_bb0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.taap.2004.06.021","article-title":"Iron metabolism and toxicity","volume":"202","author":"Papanikolaou","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tips.2021.05.001_bb0025","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","article-title":"Systemic iron homeostasis","volume":"93","author":"Ganz","year":"2013","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.tips.2021.05.001_bb0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1097-2765(00)80425-6","article-title":"A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation","volume":"5","author":"McKie","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2021.05.001_bb0035","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/35001596","article-title":"Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter","volume":"403","author":"Donovan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.tips.2021.05.001_bb0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V6.2.183.183","article-title":"Analytical review: what is the function of transferrin in plasma?","volume":"6","author":"Laurell","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.tips.2021.05.001_bb0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0014-4827(83)90415-9","article-title":"Expression of transferrin receptors during erythroid maturation","volume":"144","author":"Horton","year":"1983","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.tips.2021.05.001_bb0050","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1074\/jbc.M008922200","article-title":"Hepcidin, a urinary antimicrobial peptide synthesized in the liver","volume":"276","author":"Park","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2021.05.001_bb0055","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.tips.2021.05.001_bb0060","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1172\/JCI31342","article-title":"Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance","volume":"117","author":"Babitt","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2021.05.001_bb0065","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng1777","article-title":"Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression","volume":"38","author":"Babitt","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2021.05.001_bb0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2009.01.010","article-title":"Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression","volume":"9","author":"Gao","year":"2009","journal-title":"Cell Metab."},{"key":"10.1016\/j.tips.2021.05.001_bb0075","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","article-title":"IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin","volume":"113","author":"Nemeth","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2021.05.001_bb0080","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","article-title":"Erythroferrone inhibits the induction of hepcidin by BMP6","volume":"132","author":"Arezes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tips.2021.05.001_bb0085","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI31370","article-title":"Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)","volume":"117","author":"Peyssonnaux","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2021.05.001_bb0090","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3324\/haematol.2011.056119","article-title":"Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis","volume":"97","author":"Mastrogiannaki","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.tips.2021.05.001_bb0095","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1126\/science.3685996","article-title":"Identification of the iron-responsive element for the translational regulation of human ferritin mRNA","volume":"238","author":"Hentze","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.tips.2021.05.001_bb0100","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1126\/science.2452485","article-title":"Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation","volume":"240","author":"Casey","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.tips.2021.05.001_bb0105","doi-asserted-by":"crossref","first-page":"19906","DOI":"10.1074\/jbc.M000713200","article-title":"A novel mammalian iron-regulated protein involved in intracellular iron metabolism","volume":"275","author":"Abboud","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2021.05.001_bb0110","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1038\/41343","article-title":"Cloning and characterization of a mammalian proton-coupled metal-ion transporter","volume":"388","author":"Gunshin","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.tips.2021.05.001_bb0115","doi-asserted-by":"crossref","first-page":"24147","DOI":"10.1074\/jbc.274.34.24147","article-title":"Identification of a hypoxia response element in the transferrin receptor gene","volume":"274","author":"Lok","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2021.05.001_bb0120","doi-asserted-by":"crossref","first-page":"24142","DOI":"10.1074\/jbc.274.34.24142","article-title":"Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation","volume":"274","author":"Tacchini","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2021.05.001_bb0125","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jcp.22485","article-title":"Divalent metal transporter 1 is a hypoxia-inducible gene","volume":"226","author":"Qian","year":"2011","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.tips.2021.05.001_bb0130","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","article-title":"Hypoxia-inducible factor-2\u03b1 mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice","volume":"140","author":"Taylor","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2021.05.001_bb0135","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-\u03b1 to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.tips.2021.05.001_bb0140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.blre.2017.02.004","article-title":"New insights into iron deficiency and iron deficiency anemia","volume":"31","author":"Camaschella","year":"2017","journal-title":"Blood Rev."},{"key":"10.1016\/j.tips.2021.05.001_bb0145","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1401038","article-title":"Iron-deficiency anemia","volume":"372","author":"Camaschella","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.05.001_bb0150","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2015-05-642223","article-title":"Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women","volume":"126","author":"Moretti","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.tips.2021.05.001_bb0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejim.2017.04.018","article-title":"Clinical management of iron deficiency anemia in adults: systemic review on advances in diagnosis and treatment","volume":"42","author":"De Franceschi","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.tips.2021.05.001_bb0160","first-page":"422","article-title":"Current misconceptions in diagnosis and management of iron deficiency","volume":"15","author":"Mu\u00f1oz","year":"2017","journal-title":"Blood Transfus."},{"key":"10.1016\/j.tips.2021.05.001_bb0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nm.3814","article-title":"Anemia: progress in molecular mechanisms and therapies","volume":"21","author":"Sankaran","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2021.05.001_bb0170","first-page":"499","article-title":"The treatment of secondary hemochromatosis","volume":"106","author":"Gattermann","year":"2009","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.tips.2021.05.001_bb0175","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1586\/17474086.2016.1126176","article-title":"Clinical monitoring and management of complications related to chelation therapy in patients with \u03b2-thalassemia","volume":"9","author":"Saliba","year":"2016","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.tips.2021.05.001_bb0180","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.tips.2021.05.001_bb0185","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.05.001_bb0190","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2018.198887","article-title":"Sotatercept, a novel transforming growth factor \u03b2 ligand trap, improves anemia in \u03b2-thalassemia: a phase II, open-label, dose-finding study","volume":"104","author":"Cappellini","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.tips.2021.05.001_bb0195","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.05.001_bb0200","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ajh.24820","article-title":"Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management","volume":"92","author":"Cappellini","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tips.2021.05.001_bb0205","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2021.05.001_bb0210","first-page":"195","article-title":"Erythropoietin stimulating agents in the management of anemia of chronic kidney disease","volume":"2","author":"Hayat","year":"2008","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.tips.2021.05.001_bb0215","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.mehy.2014.02.008","article-title":"Prolyl hydroxylase domain-2 (PHD2) inhibition may be a better therapeutic strategy in renal anemia","volume":"82","author":"Soni","year":"2014","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.tips.2021.05.001_bb0220","article-title":"Limitations of serum ferritin in diagnosing iron deficiency in inflammatory conditions","volume":"2018","author":"Dignass","year":"2018","journal-title":"Int. J. Chronic Dis."},{"key":"10.1016\/j.tips.2021.05.001_bb0225","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","article-title":"Anemia of inflammation","volume":"133","author":"Weiss","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.tips.2021.05.001_bb0230","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1126\/science.aah3862","article-title":"Restored iron transport by a small molecule promotes absorption and hemoglobinization in animals","volume":"356","author":"Grillo","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.tips.2021.05.001_bb0235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bcp.13877","article-title":"Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease","volume":"85","author":"Sheetz","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tips.2021.05.001_bb0240","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-017-0427-x","article-title":"A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia","volume":"10","author":"Vadhan-Raj","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tips.2021.05.001_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212023","article-title":"First-in-human phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis","volume":"14","author":"Renders","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2021.05.001_bb0250","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1172\/JCI103786","article-title":"Transfer of iron from serum iron-binding protein to human reticulocytes","volume":"38","author":"Jandl","year":"1959","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2021.05.001_bb0255","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.18632\/oncotarget.14093","article-title":"Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism","volume":"8","author":"Rychtarcikova","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.tips.2021.05.001_bb0260","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.18632\/oncotarget.6004","article-title":"MicroRNA-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis","volume":"7","author":"Kindrat","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tips.2021.05.001_bb0265","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/cas.13234","article-title":"BRAF mutations are associated with increased iron regulatory protein-2 expression in colorectal tumorigenesis","volume":"108","author":"Horniblow","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tips.2021.05.001_bb0270","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cmet.2016.07.015","article-title":"Iron uptake via DMT1 integrates cell cycle with JAK-STAT3 signaling to promote colorectal tumorigenesis","volume":"24","author":"Xue","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.tips.2021.05.001_bb0275","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2009-11-253815","article-title":"Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway","volume":"116","author":"Cohen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.tips.2021.05.001_bb0280","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.devcel.2008.12.002","article-title":"Scara5 is a ferritin receptor mediating non-transferrin iron delivery","volume":"16","author":"Li","year":"2009","journal-title":"Dev. Cell"},{"key":"10.1016\/j.tips.2021.05.001_bb0285","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11010-017-3055-4","article-title":"SCARA5 plays a critical role in the progression and metastasis of breast cancer by inactivating the ERK1\/2, STAT3, and AKT signaling pathways","volume":"435","author":"You","year":"2017","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.tips.2021.05.001_bb0290","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1073\/pnas.0913192107","article-title":"Binding and uptake of H-ferritin are mediated by human transferrin receptor-1","volume":"107","author":"Li","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2021.05.001_bb0295","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3892\/ol.2015.3363","article-title":"Decreased expression of ferroportin in prostate cancer. Corrigendum in \/10.3892\/ol.2021.12518","volume":"10","author":"Xue","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.tips.2021.05.001_bb0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001127","article-title":"Ferroportin and iron regulation in breast cancer progression and prognosis","volume":"2","author":"Pinnix","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2021.05.001_bb0305","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1073\/pnas.0810617106","article-title":"Lipocalin 2 promotes breast cancer progression","volume":"106","author":"Yang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2021.05.001_bb0310","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1089\/ars.2012.5014","article-title":"Iron and reactive oxygen species: friends or foes of cancer cells?","volume":"20","author":"Bystrom","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.tips.2021.05.001_bb0315","doi-asserted-by":"crossref","first-page":"18748","DOI":"10.18632\/oncotarget.4349","article-title":"Targeting cancer by binding iron: dissecting cellular signaling pathways","volume":"6","author":"Lui","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tips.2021.05.001_bb0320","first-page":"1759","article-title":"Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies","volume":"46","author":"Taetle","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2021.05.001_bb0325","first-page":"57","article-title":"Preliminary clinical study of transferrin-adriamycin conjugate for drug delivery to acute leukemia patients","volume":"2","author":"Faulk","year":"1990","journal-title":"Mol. Biother."},{"key":"10.1016\/j.tips.2021.05.001_bb0330","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2217\/imt-2016-0050","article-title":"Transferrin receptor 1: a target for antibody-mediated cancer therapy.","volume":"8","author":"Daniels-Wells","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.tips.2021.05.001_bb0335","first-page":"2176","article-title":"Targeted co-delivery of the iron chelator deferoxamine and a HIF1\u03b1 inhibitor impairs pancreatic tumor growth","volume":"13","author":"Lang","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.tips.2021.05.001_bb0340","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/abbs\/gmv063","article-title":"An important role of the hepcidin\u2013ferroportin signaling in affecting tumor growth and metastasis","volume":"47","author":"Guo","year":"2015","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.tips.2021.05.001_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13143-z","article-title":"Renal clearable nanochelators for iron overload therapy","volume":"10","author":"Kang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2021.05.001_bb0350","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1182\/blood-2018-99-115339","article-title":"Transmembrane protease, serine 6 (TMPRSS6) antisense oligonucleotide (IONIS-TMPRSS6-LRX) reduces plasma iron levels of healthy volunteers in a phase 1 clinical study","volume":"132","author":"McCaleb","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tips.2021.05.001_bb0355","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2018-99-110163","article-title":"SLN124, a Galnac-siRNA conjugate targeting TMPRSS6, for the treatment of iron overload and ineffective erythropoiesis such as in beta-thalassemia","volume":"132","author":"Altamura","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tips.2021.05.001_bb0360","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/HS9.0000000000000301","article-title":"SLN124, a GalNAc-siRNA conjugate targeting TMPRSS6, efficiently prevents iron overload in hereditary haemochromatosis type 1","volume":"3","author":"Altamura","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.tips.2021.05.001_bb0365","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1182\/blood.2019003140","article-title":"Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia","volume":"135","author":"Arezes","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tips.2021.05.001_bb0370","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s42255-019-0063-6","article-title":"Nrf2 controls iron homeostasis in haemochromatosis and thalassaemia via Bmp6 and hepcidin","volume":"1","author":"Lim","year":"2019","journal-title":"Nat. Metab."},{"key":"10.1016\/j.tips.2021.05.001_bb0375","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.25670","article-title":"Oral ferroportin inhibitor VIT-2763: first-in-human, phase 1 study in healthy volunteers","volume":"95","author":"Richard","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tips.2021.05.001_bb0380","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood-2019-124059","article-title":"Proton pump inhibition for secondary hemochromatosis in hereditary anemia, a phase III placebo controlled randomized cross-over trial in progress","volume":"134","author":"Van Vuren","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.tips.2021.05.001_bb0385","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmet.2008.12.012","article-title":"Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency","volume":"9","author":"Shah","year":"2009","journal-title":"Cell Metab."},{"key":"10.1016\/j.tips.2021.05.001_bb0390","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1172\/JCI30117","article-title":"Hypoxia-inducible factor\u20132 (HIF-2) regulates hepatic erythropoietin in vivo","volume":"117","author":"Rankin","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2021.05.001_bb0395","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1172\/JCI122359","article-title":"Hepatic hepcidin\/intestinal HIF-2\u03b1 axis maintains iron absorption during iron deficiency and overload","volume":"129","author":"Schwartz","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2021.05.001_bb0400","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(14)70117-6","article-title":"The role of iron in brain ageing and neurodegenerative disorders","volume":"13","author":"Ward","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2021.05.001_bb0405","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ebiom.2019.08.014","article-title":"New insights into the role of iron in inflammation and atherosclerosis","volume":"47","author":"Cornelissen","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.tips.2021.05.001_bb0410","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrcardio.2016.185","article-title":"Inflammatory processes in cardiovascular disease: a route to targeted therapies","volume":"14","author":"Ruparelia","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.tips.2021.05.001_bb0415","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.33549\/physiolres.933589","article-title":"The role of iron in the pathogenesis of atherosclerosis","volume":"66","author":"Kraml","year":"2017","journal-title":"Physiol. Res."},{"key":"10.1016\/j.tips.2021.05.001_bb0420","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/eurheartj\/ehz112","article-title":"Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction","volume":"41","author":"Vinchi","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.tips.2021.05.001_bb0425","article-title":"Ironing out the brain","volume":"19","author":"Ward","year":"2019","journal-title":"Met. Ions Life Sci."},{"key":"10.1016\/j.tips.2021.05.001_bb0430","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/med.21631","article-title":"Hepcidin and its therapeutic potential in neurodegenerative disorders","volume":"40","author":"Qian","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.tips.2021.05.001_bb0435","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia: biologic and clinical implications","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.tips.2021.05.001_bb0440","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/cdd.2015.158","article-title":"Ferroptosis: process and function","volume":"23","author":"Xie","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.tips.2021.05.001_bb0445","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/hmg\/ddy059","article-title":"Alpha-synuclein inhibits Snx3-retromer-mediated retrograde recycling of iron transporters in S. cerevisiae and C. elegans models of Parkinson\u2019s disease","volume":"27","author":"Patel","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tips.2021.05.001_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/900a5247-7d03-4686-a544-5f7f64c0aac5","article-title":"Alpha-synuclein is a cellular ferrireductase","volume":"6","author":"Davies","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2021.05.001_bb0455","first-page":"7907","article-title":"DMT 1 inhibitor ebselen inhibits iron-induced amyloidogenic APP processing","volume":"11","author":"Xie","year":"2018","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.tips.2021.05.001_bb0460","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00775-017-1463-2","article-title":"Ebselen ameliorates \u03b2-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer\u2019s disease mice","volume":"22","author":"Xie","year":"2017","journal-title":"J. Biol. Inorg. Chem."},{"key":"10.1016\/j.tips.2021.05.001_bb0465","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fnins.2019.00180","article-title":"Iron in neurodegeneration \u2013 cause or consequence?","volume":"13","author":"Ndayisaba","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.tips.2021.05.001_bb0470","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nri3863","article-title":"Iron homeostasis in host defence and inflammation","volume":"15","author":"Ganz","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2021.05.001_bb0475","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12185-017-2366-2","article-title":"Iron and infection","volume":"107","author":"Ganz","year":"2018","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.tips.2021.05.001_bb0480","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tips.2021.05.001_bb0485","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4081\/cp.2020.1271","article-title":"COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review","volume":"10","author":"Cavezzi","year":"2020","journal-title":"Clin. Pract."},{"key":"10.1016\/j.tips.2021.05.001_bb0490","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijid.2020.05.110","article-title":"Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis?","volume":"97","author":"Edeas","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.tips.2021.05.001_bb0495","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/JLB.3A0318-108R","article-title":"Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis","volume":"105","author":"Handa","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.tips.2021.05.001_bb0500","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1242\/bio.040519","article-title":"Dietary iron restriction leads to a reduction in hepatic fibrosis in a rat model of non-alcoholic steatohepatitis","volume":"8","author":"Abe","year":"2019","journal-title":"Biol. Open"},{"key":"10.1016\/j.tips.2021.05.001_bb0505","doi-asserted-by":"crossref","first-page":"221","DOI":"10.14740\/gr1206","article-title":"Diagnosis and treatment of genetic HFE-hemochromatosis: the Danish aspect","volume":"12","author":"Milman","year":"2019","journal-title":"Gastroenterol. Res."},{"key":"10.1016\/j.tips.2021.05.001_bb0510","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-nutr-082117-051732","article-title":"Iron and cancer","volume":"38","author":"Torti","year":"2018","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.tips.2021.05.001_bb0515","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.tips.2021.05.001_bb0520","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3389\/fphar.2018.01371","article-title":"RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer","volume":"9","author":"Sui","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2021.05.001_bb0525","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41565-019-0406-1","article-title":"FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels","volume":"14","author":"Trujillo-Alonso","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.tips.2021.05.001_bb0530","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02523","article-title":"Pharmacological inhibition of cystine\u2013glutamate exchange induces endoplasmic reticulum stress and ferroptosis","volume":"3","author":"Dixon","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.tips.2021.05.001_bb0535","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ccell.2015.09.002","article-title":"Preferential iron trafficking characterizes glioblastoma stem-like cells","volume":"28","author":"Schonberg","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tips.2021.05.001_bb0540","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nnano.2016.168","article-title":"Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues","volume":"11","author":"Zanganeh","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.tips.2021.05.001_bb0545","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2015-08-663245","article-title":"Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease","volume":"127","author":"Vinchi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tips.2021.05.001_bb0550","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3389\/fimmu.2017.01479","article-title":"Iron induces anti-tumor activity in tumor-associated macrophages","volume":"8","author":"Costa da Silva","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2021.05.001_bb0555","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bj.2015.10.001","article-title":"Current and future alternative therapies for beta-thalassemia major","volume":"39","author":"de Dreuzy","year":"2016","journal-title":"Biomed. J."},{"key":"10.1016\/j.tips.2021.05.001_bb0560","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/j.bbmt.2017.12.105","article-title":"A potential therapy for beta-thalassemia (ST-400) and sickle cell disease (BIVV003)","volume":"24","author":"Holmes","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.tips.2021.05.001_bb0565","doi-asserted-by":"crossref","unstructured":"Zipkin, M. CRISPR\u2019s \u2018magnificent moment\u2019 in the clinic. Nat. Biotechnol. Published online December 6, 2019. https:\/\/doi.org\/10.1038\/d41587-019-00035-2.","DOI":"10.1038\/d41587-019-00035-2"},{"key":"10.1016\/j.tips.2021.05.001_bb0570","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/blood-2013-06-507178","article-title":"Safe mobilization of CD34+ cells in adults with \u03b2-thalassemia and validation of effective globin gene transfer for clinical investigation","volume":"123","author":"Boulad","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tips.2021.05.001_bb0575","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2019-128482","article-title":"Northstar-3: interim results from a phase 3 study evaluating lentiglobin gene therapy in patients with transfusion-dependent \u03b2-thalassemia and either a \u03b20 or IVS-I-110 mutation at both alleles of the HBB gene","volume":"134","author":"Lal","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.tips.2021.05.001_bb0580","doi-asserted-by":"crossref","first-page":"3","DOI":"10.15252\/emmm.201809958","article-title":"Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives","volume":"11","author":"Naldini","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.tips.2021.05.001_bb0585","doi-asserted-by":"crossref","first-page":"7019","DOI":"10.1038\/nature03104","article-title":"Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron","volume":"432","author":"Flo","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.tips.2021.05.001_bb0590","first-page":"3","article-title":"Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment","volume":"7","author":"Mertens","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tips.2021.05.001_bb0595","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.aaz2193","article-title":"Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.tips.2021.05.001_bb0600","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.3390\/ijms21124365","article-title":"Biological functions and therapeutic potential of lipocalin 2 in cancer","volume":"21","author":"Santiago-S\u00e1nchez","year":"2020","journal-title":"IJMS"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614721000961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614721000961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:11:27Z","timestamp":1759050687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614721000961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":120,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0165614721000961"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2021.05.001","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iron metabolism: pathophysiology and pharmacology","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2021.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}